

Typbar TCV®: Questions and answers

What is Typbar TCV?

Typbar TCV is a World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV) manufactured by Bharat Biotech. It contains the Vi capsular polysaccharide of *Salmonella enterica* serovar Typhi Ty2 conjugated to a tetanus toxoid carrier protein.

Who can receive Typbar TCV?

Typbar TCV can be administered to individuals aged 6 months of age and older.

What is the dosage schedule for Typbar TCV?

Typbar TCV is a one-dose vaccine. A single 0.5 mL dose, injected intramuscularly, provides protection for at least 4 years in adults, children, and infants over 6 months of age. In countries with a high burden of typhoid or high rates of drug-resistant typhoid, WHO recommends a booster dose, particularly for children who received a first dose younger than 2 years of age.

Is Typbar TCV safe?

WHO has reviewed clinical data and determined that Typbar TCV is safe and well-tolerated. Additionally, nearly 150 million children have safely received TCVs in introduction campaigns.

Is Typbar TCV effective?

Three large Phase 3 efficacy studies conducted in Bangladesh, Malawi, and Nepal showed that Typbar TCV prevented 79-85% of typhoid cases in children 9 months to 16 years old. These results demonstrate that Typbar TCV is protective across diverse settings in Africa and Asia.

Can Typbar TCV be given at the same time as other childhood vaccines?

Typbar TCV can be co-administered with yellow fever, measles-rubella, meningococcal conjugate vaccines, polio, and human papillomavirus vaccines.

Is Typbar TCV prequalified by WHO?

WHO prequalified Typbar TCV in January 2018, indicating it meets stringent international standards and is eligible for procurement by United Nations agencies. It is an important step for inclusion in Gavi, the Vaccine Alliance's investment strategy, which helps finance vaccine access in Gavi-eligible countries.



Bill & Melinda Gates Foundation/Sam Reinders

Typbar TCV is prepared for administration during a TyVAC effectiveness study in Nepal.

Which countries are using Typbar TCV?

Pakistan was the first country to introduce TCV into its routine immunization program in November 2019. Liberia, Samoa, and Zimbabwe introduced Typbar TCV into their routine immunization programs in 2021, followed by Kenya and Niger in 2025.

(Nepal, Malawi, Burkina Faso, Bangladesh introduced TYPHIBEV,® a comparable WHO prequalified TCV, in 2022, 2023, and 2025 respectively.)

Does Gavi support the introduction of Typbar TCV?

Gavi has provided financial support for eligible countries to introduce TCVs since 2018. Typbar TCV is available with Gavi support.

TYPHOID CONJUGATE VACCINES

What are TCVs?

TCVs are made by linking the Vi capsular polysaccharide of the typhoid bacteria to a more complex protein. Through conjugation, TCVs stimulate parts of the immune system that older typhoid vaccines cannot, thereby inducing a stronger, longer-lasting immunity among a broader age range.

What are the benefits of TCVs?

TCVs offer protection for at least four years with a single dose and are suitable for children 6 months of age and older, allowing delivery through routine childhood immunization programs. Expanded use of TCVs through routine immunization has the potential to reduce the need for antibiotics, slow further emergence of drug-resistant typhoid strains, and save lives. TCVs are projected to be one of the most impactful vaccines for preventing drug-resistance-associated deaths.

Learn more and join the effort at www.takeontyphoid.org.

#TakeOnTyphoid